TW202132346A - 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 - Google Patents

使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 Download PDF

Info

Publication number
TW202132346A
TW202132346A TW109140405A TW109140405A TW202132346A TW 202132346 A TW202132346 A TW 202132346A TW 109140405 A TW109140405 A TW 109140405A TW 109140405 A TW109140405 A TW 109140405A TW 202132346 A TW202132346 A TW 202132346A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
TW109140405A
Other languages
English (en)
Chinese (zh)
Inventor
克莉絲汀 莫瑞兒 寇可利
強納森 安卓 克路福特
威廉 湯姆士 三世 夕孟德斯
Original Assignee
瑞士商依牧諾萬科學有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商依牧諾萬科學有限公司 filed Critical 瑞士商依牧諾萬科學有限公司
Publication of TW202132346A publication Critical patent/TW202132346A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW109140405A 2019-11-19 2020-11-18 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法 TW202132346A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
US62/937,395 2019-11-19

Publications (1)

Publication Number Publication Date
TW202132346A true TW202132346A (zh) 2021-09-01

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109140405A TW202132346A (zh) 2019-11-19 2020-11-18 使用抗-fcrn抗體治療溫抗體型自體免疫性溶血性貧血之方法

Country Status (10)

Country Link
US (1) US20230049011A1 (cg-RX-API-DMAC7.html)
EP (1) EP4061486A1 (cg-RX-API-DMAC7.html)
JP (1) JP7722991B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728180A (cg-RX-API-DMAC7.html)
AU (1) AU2020387399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157797A1 (cg-RX-API-DMAC7.html)
IL (1) IL292889A (cg-RX-API-DMAC7.html)
MX (1) MX2022005862A (cg-RX-API-DMAC7.html)
TW (1) TW202132346A (cg-RX-API-DMAC7.html)
WO (1) WO2021101975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神(北京)生物制药股份有限公司 特异性识别fcrn的抗体及其用途
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
JP2025528527A (ja) * 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗FcRN抗体を用いたグレーブス病の治療方法
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
CA3157797A1 (en) 2021-05-27
MX2022005862A (es) 2022-06-23
AU2020387399A1 (en) 2022-05-19
IL292889A (en) 2022-07-01
CN114728180A (zh) 2022-07-08
US20230049011A1 (en) 2023-02-16
WO2021101975A1 (en) 2021-05-27
EP4061486A1 (en) 2022-09-28
JP7722991B2 (ja) 2025-08-13
JP2023502398A (ja) 2023-01-24
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
TWI859164B (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
US20230235063A1 (en) Antibody binding to fcrn for treating autoimmune diseases
JP2026063214A (ja) 高濃度抗c5抗体製剤
TW202136314A (zh) 抗ccr8抗體及其用途
US20230049011A1 (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
EP2377553A1 (en) Use of IL-1 antibodies for treating ophthalmic disorders
CA2447139A1 (en) Specific binding proteins and uses thereof
JP7309816B2 (ja) 結節性痒疹患者における皮膚病変およびそう痒の治療
US20260078188A1 (en) Methods of treating graves’ disease using anti-fcrn antibodies
HK40068854A (en) Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies
HK40058301B (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
HK40124168A (en) Methods of treating graves' disease using anti-fcrn antibodies
TW202417512A (zh) 含有抗tigit抗體的配製物及其使用方法
HK40058301A (en) Methods of treating graves' ophthalmopathy using anti-fcrn antibodies
TWI623324B (zh) 用於治療自體免疫病的與fcrn結合的抗體